Skip to Content
Merck

The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.

Expert opinion on pharmacotherapy (2007-08-10)
Marie-Soleil Wagner, Raquel D Arias, Deborah L Nucatola
ABSTRACT

Many factors influence the effectiveness of contraceptive methods. Oral contraceptives are the second most popular contraceptive method after female sterilization in the US. A total of 25% of women do not use their oral contraceptives correctly; 30% of women do not use them consistently. Several new contraceptive methods with alternate routes of delivery and less frequent dosing are available. The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring is marketed under the name of NuvaRing. This is the only contraceptive ring approved by the FDA. The administration of steroids by the vaginal route may offer many advantages. Because of less frequent dosing, self-administration, and possibly, an improved side effect profile, the ring has the potential to increase successful use.

MATERIALS
Product Number
Brand
Product Description

Ethinylestradiol, European Pharmacopoeia (EP) Reference Standard
Supelco
17α-Ethynylestradiol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
Ethinyl estradiol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
17α-Ethynylestradiol, ≥98%
Supelco
Ethinyl Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Etonogestrel, ≥98% (HPLC)
Ethinylestradiol for system suitability, European Pharmacopoeia (EP) Reference Standard